Moderna forecasts up to 10% revenue growth for 2026 while reducing cash cost guidance to approximately $4 billion.
Moderna revised its 2026 cash cost guidance downward to around $4 billion while maintaining its revenue growth forecast of up to 10%. The company reported Q2 2026 revenue of $0.1 billion, exceeding its projected range, but posted a net loss of $0.8 billion for the quarter.
The biotech firm ended the quarter with $6.9 billion in cash and investments. Prior guidance had not specified the cash cost target, though earlier reports suggested higher operational expenses. Analysts had anticipated a narrower loss but remained cautious on revenue growth amid competitive pressures.
No immediate market reaction was detailed in the earnings call summary.